Skip to main content
Erschienen in: Molecular Diagnosis & Therapy 5/2015

01.10.2015 | Original Research Article

Rapid and Sensitive Detection of Calreticulin Type 1 and 2 Mutations by Real-Time Quantitative PCR

verfasst von: Michael Zinke, Vanasa Nageswaran, Richard Reinhardt, Thomas Burmeister

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The majority of patients with JAK2 V617F-negative essential thrombocythemia or primary myelofibrosis harbor mutations involving the calreticulin (CALR) gene. These mutations are located in CALR exon 9 and lead to a frameshift with subsequent alteration of the CALR protein C-terminus. They have emerged as valuable molecular markers for the diagnosis of clonal myeloproliferative diseases. Although a variety of CALR mutations have been described, two mutations, denoted type 1 and type 2, account for around 85 % of cases. The type 1 mutation encompasses a 52 bp deletion and the type 2 mutation a 5 bp TTGTC insertion.

Methods

This work describes the development and testing of quantitative real-time PCRs (qPCRs) for detecting these two mutations.

Results

The final type 1 CALR qPCR displayed a sensitivity of <0.1 % mutant alleles and the type 2 CALR qPCR had a sensitivity of <0.01 % mutant alleles. Additionally, two new CALR mutations are reported.

Conclusion

These sensitive and specific qPCRs should be helpful in establishing the diagnosis and in monitoring minimal residual disease in patients during or after therapy.
Literatur
1.
Zurück zum Zitat de Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia. 2006;20:200–5.CrossRefPubMed de Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia. 2006;20:200–5.CrossRefPubMed
2.
Zurück zum Zitat Vardiman J, Hyjek E. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Hematology Am Soc Hematol Educ Program. 2011;2011:250–6.CrossRefPubMed Vardiman J, Hyjek E. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Hematology Am Soc Hematol Educ Program. 2011;2011:250–6.CrossRefPubMed
3.
Zurück zum Zitat Savage N, George TI, Gotlib J. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. Int J Lab Hematol. 2013;35:491–500.CrossRefPubMed Savage N, George TI, Gotlib J. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. Int J Lab Hematol. 2013;35:491–500.CrossRefPubMed
4.
Zurück zum Zitat Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41:461–76.CrossRefPubMed Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41:461–76.CrossRefPubMed
5.
Zurück zum Zitat Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.CrossRefPubMed Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.CrossRefPubMed
6.
Zurück zum Zitat Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.PubMedCentralCrossRefPubMed Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28:1568–70.CrossRefPubMed Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28:1568–70.CrossRefPubMed
8.
Zurück zum Zitat Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013;27:2032–9.PubMedCentralCrossRefPubMed Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013;27:2032–9.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, et al. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014;99:1492–8.PubMedCentralCrossRefPubMed Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, et al. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014;99:1492–8.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Burmeister T, Marschalek R, Schneider B, Meyer C, Gökbuget N, Schwartz S, et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia. 2006;20:451–7.CrossRefPubMed Burmeister T, Marschalek R, Schneider B, Meyer C, Gökbuget N, Schwartz S, et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia. 2006;20:451–7.CrossRefPubMed
11.
Zurück zum Zitat Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. 2001;Chapter 9:Unit 9.8:9.8.1–9.8.12. Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. 2001;Chapter 9:Unit 9.8:9.8.1–9.8.12.
12.
Zurück zum Zitat Liu J, Huang S, Sun M, Liu S, Liu Y, Wang W, et al. An improved allele-specific PCR primer design method for SNP marker analysis and its application. Plant Methods. 2012;8:34.PubMedCentralCrossRefPubMed Liu J, Huang S, Sun M, Liu S, Liu Y, Wang W, et al. An improved allele-specific PCR primer design method for SNP marker analysis and its application. Plant Methods. 2012;8:34.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013–34.CrossRefPubMed van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013–34.CrossRefPubMed
14.
Zurück zum Zitat Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28:1407–13.CrossRefPubMed Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28:1407–13.CrossRefPubMed
15.
Zurück zum Zitat Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.CrossRefPubMed Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.CrossRefPubMed
16.
Zurück zum Zitat Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N, et al. JAK2 p. V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98:722–8.PubMedCentralCrossRefPubMed Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N, et al. JAK2 p. V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98:722–8.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Bar M, Radich J. Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia. J Natl Compr Canc Netw. 2013;11:308–15.PubMed Bar M, Radich J. Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia. J Natl Compr Canc Netw. 2013;11:308–15.PubMed
18.
Zurück zum Zitat Zhang WW, Habeebu S, Sheehan AM, Naeem R, Hernandez VS, Dreyer ZE, et al. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant. J Pediatr Hematol Oncol. 2009;31:879–83.CrossRefPubMed Zhang WW, Habeebu S, Sheehan AM, Naeem R, Hernandez VS, Dreyer ZE, et al. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant. J Pediatr Hematol Oncol. 2009;31:879–83.CrossRefPubMed
19.
Zurück zum Zitat Barraco D, Carobolante F, Candoni A, Simeone E, Piccaluga P, Tabanelli V, et al. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy. Eur J Haematol. 2014;92:541–5.CrossRefPubMed Barraco D, Carobolante F, Candoni A, Simeone E, Piccaluga P, Tabanelli V, et al. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy. Eur J Haematol. 2014;92:541–5.CrossRefPubMed
20.
Zurück zum Zitat Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014;123:3574–7.PubMedCentralCrossRefPubMed Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014;123:3574–7.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E. Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation.[letter]. Br J Haematol. 2014;166(5):800–2.CrossRefPubMed Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E. Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation.[letter]. Br J Haematol. 2014;166(5):800–2.CrossRefPubMed
22.
Zurück zum Zitat Lim KH, Lin HC, Chen CG, Wang WT, Chang YC, Chiang YH, et al. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clin Chim Acta. 2015;440:133–9.CrossRefPubMed Lim KH, Lin HC, Chen CG, Wang WT, Chang YC, Chiang YH, et al. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clin Chim Acta. 2015;440:133–9.CrossRefPubMed
23.
Zurück zum Zitat Chi J, Manoloukos M, Pierides C, Nicolaidou V, Nicolaou K, Kleopa M, et al. Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring. Ann Hematol. 2015;94:399–408.CrossRefPubMed Chi J, Manoloukos M, Pierides C, Nicolaidou V, Nicolaou K, Kleopa M, et al. Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring. Ann Hematol. 2015;94:399–408.CrossRefPubMed
24.
Zurück zum Zitat Yao QM, Zhou J, Gale RP, Li JL, Li LD, Li N, et al. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. Hematology. 2015. doi:10.1179/1607845415y.0000000009 Yao QM, Zhou J, Gale RP, Li JL, Li LD, Li N, et al. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. Hematology. 2015. doi:10.​1179/​1607845415y.​0000000009
25.
Zurück zum Zitat Jones AV, Ward D, Lyon M, Leung W, Callaway A, Chase A, et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res. 2015;39:82–7.CrossRefPubMed Jones AV, Ward D, Lyon M, Leung W, Callaway A, Chase A, et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res. 2015;39:82–7.CrossRefPubMed
Metadaten
Titel
Rapid and Sensitive Detection of Calreticulin Type 1 and 2 Mutations by Real-Time Quantitative PCR
verfasst von
Michael Zinke
Vanasa Nageswaran
Richard Reinhardt
Thomas Burmeister
Publikationsdatum
01.10.2015
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 5/2015
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-015-0162-3

Weitere Artikel der Ausgabe 5/2015

Molecular Diagnosis & Therapy 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.